Discovery Laboratories,
Inc. DSCO today announced it has received a patent issued by the
United States Patent and Trademark Office (USPTO) entitled "Pulmonary
Surfactant Formulations." The claims of the patent (U.S. Patent Number
8,337,815) provide coverage for synthetic pulmonary surfactant compositions
comprising a combination of a proprietary synthetic peptide and various
lipids. The patent term expires in December 2028.
This patent provides exclusivity for new formulations of KL4 surfactant and is
separate and distinct from the patent portfolios covering SURFAXIN, the
Company's lead KL4 surfactant product, and AEROSURF^®, the Company's lead KL4
surfactant development program.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in